Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| 89bio Inc | ETNB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 8.58 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.58 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 6.575 - 22.93 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 8.58 | USD |
89bio (ETNB) Options Flow Summary
89bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 802.24M | 93.50M | - | 0 | -142.19M | -1.52 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
89bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ETNB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.15 | 9.78 | 8.54 | 8.94 | 776,226 | -0.57 | -6.23% |
| 1 Month | 11.52 | 11.69 | 8.54 | 10.02 | 776,804 | -2.94 | -25.52% |
| 3 Months | 9.99 | 16.63 | 7.47 | 11.00 | 1,303,072 | -1.41 | -14.11% |
| 6 Months | 7.00 | 16.63 | 6.60 | 10.19 | 1,304,741 | 1.58 | 22.57% |
| 1 Year | 15.50 | 22.93 | 6.575 | 12.95 | 1,355,849 | -6.92 | -44.65% |
| 3 Years | 25.93 | 27.99 | 2.00 | 11.83 | 890,902 | -17.35 | -66.91% |
| 5 Years | 20.00 | 47.2532 | 2.00 | 12.70 | 636,160 | -11.42 | -57.10% |
89bio Description
| 89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast growth factor 21 (FGF21) is developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). |
